Innovative Research


he LMIC-adapted Cryopen® is a treatment device especially designed for use in low-resource settings.


The WiSAP LMIC- adapted Thermoablation device uses heat instead of cold to treat cervical precancer.

BHI and the Cleveland Clinic have been working on this since 2015 and in May, we presented our preliminary results at the NCI’s headquarters. We also conducted hands-own workshops to demonstrate the use of both devices and have received an overwhelmingly positive response from medical providers around the world.

Sponsored by the National Cancer Institute Affordable Cancer Technologies Program (NCI ACT), additional research will test the effectiveness and safety of both portable treatments. The CryoPen and the Thermoablation. Both have the potential to revolutionize the field of cervical cancer prevention by making treatment available in even the most remote locations.

A randomized control trial enrollment is underway to test the efficacy of CryoPen® cryotherapy and the Wisap® LMIC adapted thermoablator in El Salvador and Colombia. In 2018 we will start to enroll patients in an additional site in Peru. Cleveland Clinica and BHI were able to secure funds from the Rising Tide Foundation to include thermoablation in the evaluation of these technologies.

BHI is also subcontracted by the Cleveland Clinic in an R01 grant from the NIH (a medical-industry partnership grant) to test different protocolos of applications with the LMIC-adapted thermoablator. Supplement funding to expand the trial was awarded by the Gateway for Cancer Research. Work on the prototype of this device is currently ongoing and we will start enrollment of patients in Mexico in mid-2018.

HRME: High Resolution Micro Endoscopy

The HRME imaging system is intended to be a low-cost, innovative technique that allows real-time, point-of-care detection of high-grade precancerous cervical lesions without a biopsy being performed. To date, we have enrolled more than 900 women in this project.

Cervical Cancer Screening in Transgender Men

BHI conducted one of the first studies testing the acceptability of HPV tests as a cervical cancer screening method among transgender men in a LMIC.

In partnership with the non profit organization Generación Hombres Trans of San Salvador, we offered HPV self-collected tests and comprehensive physical exams to transgender men. Most of them accepted the HPV self-collection. We hope that the use of HPV self-sampling tests in transgender men is a viable method that can significantly improve the participation and acceptance of cervical cancer screening in a LMIC setting.